Get the Stockscreener App
1.80
3.45%
0.06
Metagenomi Inc stock is traded at $1.80, with a volume of 283.19K.
It is up +3.45% in the last 24 hours and up +1.12% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
See More
Previous Close:
$1.74
Open:
$1.75
24h Volume:
283.19K
Relative Volume:
0.50
Market Cap:
$67.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.11%
1M Performance:
+1.12%
6M Performance:
+6.51%
1Y Performance:
-45.45%
1-Day Range:
$1.75
$1.845
1-Week Range:
$1.59
$1.845
52-Week Range:
$1.23
$4.00
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
1.80 | 65.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
Is Metagenomi Inc. stock attractive after correctionHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - ulpravda.ru
Will Metagenomi Inc. stock attract ESG investors2026 world cup usa national team final top scorers transition play group prediction expert opinion - ulpravda.ru
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Fed Impact: Is Metagenomi Inc stock undervalued vs historical averagesCEO Change & Reliable Breakout Forecasts - moha.gov.vn
Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Metagenomi (NASDAQ:MGX) - Defense World
Short Interest in Metagenomi, Inc. (NASDAQ:MGX) Grows By 27.1% - Defense World
Irish Jian, Metagenomi CEO, sells $2899 in MGX stock - Investing.com
Irish Jian, Metagenomi CEO, sells $2899 in MGX stock By Investing.com - Investing.com UK
Metagenomi Earnings Notes - Trefis
CEO Moves: Can Metagenomi Inc stock weather global recession2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - moha.gov.vn
Why analysts upgrade Metagenomi Inc. stock2025 Price Targets & High Win Rate Trade Alerts - Улправда
Why Metagenomi Inc. stock attracts global investorsJuly 2025 Weekly Recap & Real-Time Market Trend Scan - Улправда
Is Metagenomi Inc. stock in correction or buying zoneMarket Risk Report & Community Shared Stock Ideas - bolumsonucanavari.com
Is Metagenomi Inc. stock recession proofJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Is Metagenomi Inc. stock positioned well for digital economy2025 Technical Patterns & Expert Approved Trade Ideas - DonanımHaber
Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Thomas Brian C. sells $6786 in Metagenomi (MGX) stock By Investing.com - Investing.com Australia
Irish Jian, Metagenomi CEO, sells $2838 in MGX stock - Investing.com India
Metagenomi CFO Wapnick sells $2792 in shares By Investing.com - Investing.com Australia
Irish Jian, Metagenomi CEO, sells $2838 in MGX stock By Investing.com - Investing.com Australia
Metagenomi general counsel Wein sells $352 in stock By Investing.com - Investing.com Nigeria
Thomas Brian C. sells $6786 in Metagenomi (MGX) stock - Investing.com
Metagenomi general counsel Wein sells $352 in stock - Investing.com
Will Metagenomi Inc. stock deliver consistent dividendsBull Run & Technical Pattern Based Signals - Newser
Pura Vida Investments LLC Grows Stock Position in Metagenomi, Inc. $MGX - MarketBeat
Metagenomi’s general counsel Wein sells $360 in stock - Investing.com India
Metagenomi’s general counsel Wein sells $360 in stock By Investing.com - Investing.com Nigeria
Thomas Brian C. sells Metagenomi (MGX) shares worth $4888 By Investing.com - Investing.com Canada
Metagenomi CFO Wapnick sells $2852 in shares By Investing.com - Investing.com Canada
Thomas Brian C. sells Metagenomi (MGX) shares worth $4888 - Investing.com India
Metagenomi CFO Wapnick sells $2852 in shares - Investing.com
CEO Irish Surrenders 1,602 Of Metagenomi Inc [MGX] - TradingView
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - marketscreener.com
Metagenomi (Nasdaq: MGX) to unveil APOC3 preclinical data from Ionis collaboration at 2025 Nature conference - Stock Titan
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):